Expert: FDA’s draft guidance on particle inspections takes different approach than compendial method
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy